(R)-1-((tert-butyldimethylsilyl)oxy)but-3-en-2-amine | 184846-91-1

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: (R)-1-((tert-butyldimethylsilyl)oxy)but-3-en-2-amine
• 英文别名: (2R)-1-[tert-butyl(dimethyl)silyl]oxybut-3-en-2-amine
• CAS: 184846-91-1
• 化学式: C₁₀H₂₃NOSi
• 分子量: 201.384
• InChiKey: SOKFJPGUYADDIL-SECBINFHSA-N

物化性质

• 沸点：
  226.5±20.0 °C(Predicted)
• 密度：
  0.857±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-1-((tert-butyldimethylsilyl)oxy)but-3-en-2-amine 在 4-二甲氨基吡啶 、 sodium cyanoborohydride 作用下， 以 二氯甲烷 、 2,2,2-三氟乙醇 为溶剂， 反应 6.0h， 生成 (2S,3R,4S,6R)-2-(((2R,3R,4R,6R)-7-((tert-butoxycarbonyl)((R)-1-((tertbutyldimethylsilyl)oxy)but-3-en-2-yl)amino)-4-methoxy-4,6-dimethyl-2-(2,2,5-trimethyl-4-oxo-4H-1,3-dioxin-6-yl)heptan-3-yl)oxy)-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate
  参考文献：
  名称：

  WO2020106627A5

  摘要：

  公开号：

  WO2020106627A5
• 作为产物：
  描述：

  叔丁基二甲基氯硅烷 在 咪唑 、 氨 、 sodium 作用下， 以 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 11.67h， 生成 (R)-1-((tert-butyldimethylsilyl)oxy)but-3-en-2-amine
  参考文献：
  名称：

  Huwe, Christoph M.; Velder, Janna; Blechert, Siegfried, Angewandte Chemie, 1996, vol. 108, # 20, p. 2542 - 2544

  摘要：

  DOI：

文献信息

• [EN] BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSÉS DE CARBAMOYLPYRIDONE TRICYCLIQUE PONTÉS ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：GILEAD SCIENCES INC

  公开号：WO2020197991A1

  公开（公告）日：2020-10-01

  Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明揭示了用于治疗或预防人类免疫缺陷病毒（HIV）感染的化合物。这些化合物具有以下式（I）：包括立体异构体和其药用可接受的盐，其中R1、R2、L、W1、W2、X、Y和Z如本文所定义。本发明还揭示了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• A Flexible Synthesis of Azasugars and Homoazasugars via Olefin Metathesis
  作者：Christoph M. Huwe、Siegfried Blechert

  DOI：10.1055/s-1997-1497

  日期：1997.1

  A flexible synthesis of azasugars and homoazasugars from vinyl glycine methyl ester is described. The syntheses, which are based on ring closing olefin metathesis steps and stereocontrolled functionalizations of the formed double bonds, offer a broad variability of functionalization and stereochemistry of the products.

  本文介绍了从乙烯基甘氨酸甲酯灵活合成氮杂杉糖和均氮杂杉糖的方法。该合成方法基于闭环烯烃偏析步骤和对所形成双键的立体控制官能化，可为产物的官能化和立体化学提供广泛的可变性。
• WO2008/151304
  申请人：——

  公开号：——

  公开（公告）日：——
• A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration
  作者：Dean A. Heathcote、Hetal Patel、Sebastian H. B. Kroll、Pascale Hazel、Manikandan Periyasamy、Mary Alikian、Seshu K. Kanneganti、Ashutosh S. Jogalekar、Bodo Scheiper、Marion Barbazanges、Andreas Blum、Jan Brackow、Alekasandra Siwicka、Robert D. M. Pace、Matthew J. Fuchter、James P. Snyder、Dennis C. Liotta、Paul. S. Freemont、Eric O. Aboagye、R. Charles Coombes、Anthony G. M. Barrett、Simak Ali

  DOI：10.1021/jm100732t

  日期：2010.12.23

  Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression. Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs. Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compound, 4k (BS-194), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, respectively). Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G(2)/M phases. Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI(50) = 280 nmol/L). Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice. When administered at a concentration of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation. These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.
• WO2020106627A5
  申请人：——

  公开号：WO2020106627A5

  公开（公告）日：2022-11-29